XWAR
CRM
Market cap11mUSD
Oct 09, Last price
0.51PLN
1D
1.19%
1Q
4.08%
Jan 2017
-75.48%
IPO
-87.40%
Name
PZ Cormay SA
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
PZ Cormay S.A., a diagnostic company, provides IVD solutions in Poland and internationally. The company offers analyzers, reagents, cleaning liquids, calibrators, control materials, patterns, and agglutination tests. It also provides analyzers, test strips, inspections, and calibration strips. In addition, the company offers parasitology, such as Paragreen Mini-System, a specialized device for concentrating and preserving stool samples, as well as veterinary medicines. Further, it provides immunochemistry, including SNIBE, MINDRAY, DIESSE, and AliveDX, as well as molecular biology, such as RT-PCR systems, systems for isolating genetic material, workstations, RT-PCR reagent kits, and nucleic acid isolation reagent kits. Additionally, the company offers sampling comprising blood and urine samples and supporting materials, as well as Sentimag systems, Magtrace markers, Magseed Markers, and surgical instruments, as well as HPLC systems, point of care diagnostics, and integrated systems. The company was founded in 1985 and is based in Lomianki, Poland.
Related entities
Subsidiaries
Orphee SA
Key people
Flavio Finoletto
President of the Management Board · since 2023
Wojciech Suchowski
Vice President of the Management Board · since 2014
Witold Rebacz
Chief Accounting Officer
Kamil Gewartowski
Member of the Supervisory Board · since 2023
Tomasz Markowski
Member of the Supervisory Board · since 2016
Member of the Supervisory Board · since 2023
Marcin Sieczek
Member of the Supervisory Board · since 2023
Legal address
Łomianki Wiosenna 22
Łomianki, 14 05-092
PL
Łomianki, 14 05-092
PL
Headquarters
Warszawa Puławska 303
Warszawa, 14 02-785
PL
Warszawa, 14 02-785
PL
Valuation
Title PLN in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||